Clinical trial · Observational
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223
NCT02899104CI-TRIAL-00044371NavigantcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms, Castration-Resistant | Prostate Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Xofigo (Radium-223 dichloride, BAY88-8223) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Radium-223 dichloride
- description
- Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.
- interventionNames
- Drug: Xofigo (Radium-223 dichloride, BAY88-8223)
Primary outcomes (1)
- measure
- Determining factors that drive physician decision for treatment selection.
- timeFrame
- Up to 9 months
- description
- The treating physician should select out of the following options: Prostate Specific Antigen rising, Alkaline phosphatase (ALP) , Lactate dehydrogenase (LHD), testosterone, pain, symptoms, bone lesions, disease progression.
Secondary outcomes (23)
- measure
- Most common treatment sequences
- timeFrame
- Up to 9 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart. * Patients were at least 18 years of age as of the first diagnosis for mCRPC. * Patients must have received at least one intravenous injection of Radium-223 (Xofigo). * First injection of Radium-223 must have started between periods 1-January-2014 to 30-June-2014 or 15-November-2014 to present. * Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose. Exclusion Criteria: * Patients who received Radium-223 as part in an interventional clinical trial * Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.